XTX Topco Ltd Has $39,000 Stock Holdings in Nektar Therapeutics $NKTR

Key Points

• XTX Topco Ltd has reduced its stake in Nektar Therapeutics by 76.5%, now owning only 57,418 shares after selling 187,283 shares.
• Analysts have mixed views on Nektar, with one downgrading the stock to "sell," while six have issued "buy" ratings, reflecting a total average price target of $88.33.
• Nektar Therapeutics reported earnings of ($2.95) per share, beating estimates, with revenues of $11.18 million for the last quarter.

XTX Topco Ltd trimmed its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 76.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 57,418 shares of the biopharmaceutical company's stock after selling 187,283 shares during the quarter. XTX Topco Ltd's holdings in Nektar Therapeutics were worth $39,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of NKTR. Nantahala Capital Management LLC increased its holdings in Nektar Therapeutics by 90.0% in the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company's stock valued at $7,263,000 after buying an additional 3,700,000 shares during the period. Woodline Partners LP increased its holdings in Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company's stock valued at $4,626,000 after buying an additional 3,242,841 shares during the period. Renaissance Technologies LLC increased its holdings in Nektar Therapeutics by 17.5% in the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock valued at $3,637,000 after buying an additional 583,153 shares during the period. 22NW LP bought a new position in Nektar Therapeutics in the 4th quarter valued at about $2,038,000. Finally, Mackenzie Financial Corp increased its holdings in Nektar Therapeutics by 253.1% in the 1st quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company's stock valued at $1,128,000 after buying an additional 1,188,976 shares during the period. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Stock Performance

Shares of NKTR traded up $1.05 during mid-day trading on Thursday, reaching $28.00. The company had a trading volume of 816,077 shares, compared to its average volume of 659,475. The company's 50 day simple moving average is $22.50 and its 200 day simple moving average is $14.96. Nektar Therapeutics has a 1-year low of $6.45 and a 1-year high of $37.38. The company has a market capitalization of $532.56 million, a price-to-earnings ratio of -3.18 and a beta of 0.95.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) earnings per share for the quarter, beating analysts' consensus estimates of ($3.13) by $0.18. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. The company had revenue of $11.18 million for the quarter, compared to the consensus estimate of $9.42 million. As a group, equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 1,573 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $26.59, for a total value of $41,826.07. Following the sale, the chief executive officer directly owned 69,340 shares in the company, valued at approximately $1,843,750.60. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 2,974 shares of company stock valued at $79,079. Company insiders own 5.25% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright raised their target price on shares of Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. B. Riley raised their target price on shares of Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Wall Street Zen lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. Finally, BTIG Research raised their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Nektar Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $88.33.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.